Healthcare Industry News: Bard
News Release - March 24, 2017
Reata Pharmaceuticals, Inc. Appoints David Chapman as Vice President, MarketingIRVING, Texas, March 24, 2017 -- (Healthcare Sales & Marketing Network) -- Reata Pharmaceuticals, Inc. (RETA) (“Reata” or the “Company”) today announced the appointment of David Chapman as Vice President, Marketing.
Mr. Chapman joins the company with over 25 years of biopharmaceutical sales, marketing, and market access experience. Over the past decade, he served in leadership roles at Relypsa, Boehringer Ingelheim, and Pfizer. During his tenure at Boehringer Ingelheim, Mr. Chapman served as the Global Marketing lead for an interferon-free asset for hepatitis C and led Global Market Access activities across a broad range of therapeutic areas such as oncology, respiratory diseases, Alzheimer’s disease, and diabetes. Most recently, Mr. Chapman served as the Director of Managed Markets at Relypsa where he led a team of National and Regional Account Managers that gained new or improved access for Veltassa for over 50 million lives.
“We are pleased to welcome David to the role of Vice President, Marketing,” said Dawn Bir, Reata’s Chief Commercial Officer. “David brings a wealth of both strategic and tactical experience in both marketing and market access, which are critical areas to the commercial success of Reata. He is ideally suited to help lead the commercial development of our brands and important collaborations with key stakeholders.”
Mr. Chapman received a B.S. in Management from Auburn University, Auburn, AL.
About Reata Pharmaceuticals, Inc.
Reata Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata’s two most advanced clinical candidates (Bardoxolone methyl and omaveloxolone) target an important transcription factor, called Nrf2, to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.
This press release includes certain disclosures which contain “forward-looking statements,” including, without limitation, statements regarding the success, cost and timing of our product development activities and clinical trials, our plans to research, develop and commercialize our product candidates, and our ability to obtain and retain regulatory approval of our product candidates. You can identify forward-looking statements because they contain words such as “believes,” “will,” “may,” “aims,” “plans” and “expects.” Forward-looking statements are based on Reata’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in Reata’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K, under the caption “Risk Factors.” The forward-looking statements speak only as of the date made and, other than as required by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Source: Reata Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.